Baeocystin

Chemist and mycologist Jochen Gartz reported in the 1990s that baeocystin is active as a psychedelic in humans. He has stated that 4mg produced a "threshold" or "gentle hallucinogenic experience" with "mild hallucinations for three hours" and that "10mg of baeocystin [was] found to be about as psychoactive as a similar amount of psilocybin". Conversely, he has claimed that accidental ingestion of Inocybe aeruginascens, which contains high levels of both aeruginascin (4-PO-TMT) and baeocystin, is usually associated with euphoric experiences, in contrast to the dysphoric experiences that can occur with mushrooms containing only high levels of psilocybin. ==Interactions==

Baeocystin is thought to be a prodrug of norpsilocin, analogously to how psilocybin is a prodrug of psilocin. Norpsilocin is a potent and centrally penetrant agonist of the serotonin 5-HT2A receptor and also interacts with other serotonin receptors. ==Chemistry==

Analogues Analogues of baeocystin include 4-HO-NMT, norbaeocystin (4-PO-T), psilocybin (4-PO-DMT), psilocin (4-HO-DMT), ethocybin (4-PO-DET), and aeruginascin (4-PO-TMT), among others. ==Natural occurrence==

Baeocystin was first isolated from the mushroom Psilocybe baeocystis, and later from P. semilanceata, Panaeolus renenosus, Panaeolus subbalteatus, and Copelandia chlorocystis. ==History==

Baeocystin was first synthesized by Troxler and colleagues in 1959. ==Research==

Baeocystin is being evaluated by Pilz Bioscience ("pilz" being German for "mushroom") under the developmental code name PLZ-1019 for the possible treatment of pervasive developmental disorders like autism in children. ==See also==